Gerard M. Nolan MD, F.A.C.S. Nolan Eye & Laser Center
The purpose of this web presentation is to share with Dr Nolan’s peers and their patients his 24-year experience of treating Stargardt disease with off-label use of echothiophate iodide. Dr Nolan has successfully treated Stargardt Disease patients with the application of a topical cholinergic medication (TCM), i.e., low dose echothiophate iodide. He has treated more than 350 Stargardt Disease patients. Most patients have shown a delay in degradation and/or sustained improvement of visual acuity and color vision over many years. After beginning topical echothiophate, visual acuity improvement is immediate, occurring after the first application of the medication. The treatment is especially effective in patients with baseline best corrected visual acuity (BCVA) of between 20/200 and 20/400 and baseline BCVA less than 20/400.
The following papers present the results of Dr. Nolan’s work and are available for review.
Dr Nolan’s goal is to have the maximum number of Stargardt Disease sufferers benefit from his treatment protocol. Patients have traveled from almost all of the United States and many countries to be evaluated for treatment of Stargardt disease with echothiophate. However, since multiple visits to his Farmington, Connecticut office are required during the first year of treatment, this can be a financial burden for many patients. Dr. Nolan hopes that ophthalmologists across the country will adopt his protocol and treat patients locally.
This presentation is intended for use by ophthalmologists only and is not intended to suggest or encourage any type of self-diagnosis or self-treatment of any eye disease. It is hoped this presentation may expand possible treatments for patients under the care of their ophthalmologists.
There are no conflicts of interest in this shared research. There has been no financial support, contribution or grant funding received from any individual or organization.
For more patient case studies and information please contact